Dr. Paul Sax asks if fluvoxamine could be the first effective, inexpensive, widely available outpatient treatment for COVID-19, in
HIV and ID Observations.
A rarely used antidepressant has quietly been going through high-quality clinical studies for the treatment of COVID-19. In the latest HIV and ID Observations, Dr. Paul Sax wonders if we might finally be onto something, even after stumbling numerous times with hydroxychloroquine, lopinavir-ritonavir, and ivermectin.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.